Tevogen Bio Highlights Most Recent Insider Ownership of 74%; Management Maintains Conviction in the Company’s Mission

WARREN, N.J., April 07, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a healthcare company with dedicated efforts in immunotherapy and artificial intelligence, is unified by a commitment to advancing patient-centric solutions. The Company’s clinical-stage immunotherapy effort, Tevogen Bio, focuses on the development of off-the-shelf, genetically unmodified T cell therapeutics for infectious diseases and cancers. Its artificial intelligence effort, Tevogen.AI, aims to advance innovation in drug discovery, clinical trial efficiency, and patient access. Together, these efforts represent the foundational pillars of Tevogen’s broader vision to redefine the future of medicine.

Read more at globenewswire.com